Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

axitinib

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

National Institute for Health and Care Excellence NICE logo

NICE gives nod to Gilead’s Zydelig

First class of drug to be recommended for leukaemia

- PMLiVE

Pfizer launches first self-injectable contraceptive in UK

New option for female contraception hits UK

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

Study clears Pfizer’s Champix of serious risks

Smoking-cessation drug 'does not increase risk' of depression or heart attacks

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links